Document:

<PAGE>
                                                                    EXHIBIT 10.2

                         CONSENT AGREEMENT AND AMENDMENT

         This Agreement (the "Agreement") dated February 25, 2004 (the
"Effective Date") is made by and among Wyeth Holdings Corporation (formerly
known as "American Cyanamid Company"), 5 Giralda Farms, Madison, New Jersey
07940 ("Wyeth"), Neurocrine Biosciences, Inc., 10555 Science Center Drive, San
Diego, California 92121 ("Neurocrine"), and DOV Pharmaceutical, Inc., 433
Hackensack Avenue, Hackensack, New Jersey 07601 ("DOV"). Wyeth, Neurocrine and
DOV may each be referred to herein individually as a "Party" and collectively as
the "Parties".

         WHEREAS, DOV and Wyeth entered into that certain License Agreement
dated May 29, 1998 (as amended from time to time, including, without limitation,
by the 2002 Consent Agreement, the "Original License Agreement") pursuant to
which DOV was granted an exclusive license from Wyeth to the compound designated
as CL 285,489 (the "Compound");

         WHEREAS, DOV and Neurocrine entered into that certain Sublicense and
Development Agreement dated June 30, 1998 (as amended from time to time,
including, without limitation, by this Agreement and by the 2002 Consent
Agreement, the "Sublicense Agreement") pursuant to which DOV sublicensed to
Neurocrine its rights under the Original License Agreement in the Patent Rights
and Know-How (each as defined in the Sublicense Agreement) to, among other
things, make and sell the Licensed Product (as defined in the Sublicense
Agreement);

         WHEREAS, DOV, Neurocrine and Wyeth entered into that certain Consent
and Agreement dated December 13, 2002 (the "2002 Consent Agreement"), pursuant
to which Wyeth and DOV, inter alia, provided their consent for Neurocrine to
further sublicense to an Approved Sublicensee (as defined therein), including
Pfizer, Inc., the rights granted to it under the Sublicense Agreement;

         WHEREAS, DOV and Wyeth desire to enter into prior to or upon the
Closing (as defined below) (i) an Amended and Restated License Agreement,
pursuant to which the Original License Agreement will be amended to delete
therefrom all rights and obligations of each of Wyeth and DOV insofar as they
relate to the Compound, and (ii) the Compound License Agreement (as defined
below), setting forth the rights and obligations of each of Wyeth and DOV solely
as they relate to the Compound; and

         WHEREAS, Neurocrine desires to obtain from Wyeth and Wyeth desires to
grant to Neurocrine an assignment of (i) all of Wyeth's rights and obligations
under each of the Compound License Agreement, (ii) Wyeth's rights and
obligations under the 2002 Consent Agreement the extent such rights and
obligations relate to the Compound or the Compound Patent, and (iii) all of
Wyeth's right, title and interest in and to the Compound Patent (as defined
below), in each case subject to the rights and licenses granted to DOV pursuant
to the Compound License Agreement and the rights and licenses granted to DOV and
Neurocrine under the 2002 Consent Agreement.

                                       1
<PAGE>

         NOW THEREFORE, in consideration of the foregoing premises and the
promises, mutual covenants and obligations set forth below, and other good and
valuable consideration, the Parties agree as follows.

1.       DEFINITIONS.

         1.1      INCORPORATION BY REFERENCE. All capitalized terms not
                  otherwise defined herein shall have the meanings assigned to
                  such terms in the Original License Agreement or the Sublicense
                  Agreement, as applicable.

         1.2      "CLOSING" shall mean the date and time on which Wyeth assigns
                  to Neurocrine and Neurocrine assumes from Wyeth, all of
                  Wyeth's rights and obligations under the Compound License
                  Agreement.

         1.3      "COMPOUND LICENSE AGREEMENT" shall mean the license agreement
                  relating solely to the Compound, which license agreement is to
                  be entered into by and between Wyeth and DOV simultaneously
                  with their amendment and restatement of the Original License
                  Agreement as described above in the preamble of this
                  Agreement. The Compound License Agreement shall be in the form
                  attached hereto as Exhibit 1.3.

         1.4      "COMPOUND PATENT" shall mean United States Patent 6,399,621
                  granted on June 4, 2002.

2.       CONSENTS.

         2.1      CONSENT TO AMEND THE LICENSE AGREEMENT. Neurocrine hereby
                  acknowledges that Wyeth and DOV will, and Wyeth and DOV each
                  agree that they shall, on or before the Closing, (i) amend and
                  restate the Original License Agreement so as to delete
                  therefrom all rights and obligations of each of Wyeth and DOV
                  insofar as they relate to the Compound, and (ii)
                  simultaneously enter into the Compound License Agreement.
                  Neurocrine hereby provides its consent for Wyeth and DOV to so
                  amend the Original License Agreement and enter into the
                  Compound License Agreement.

         2.2      CONSENT TO ASSIGN THE COMPOUND LICENSE AGREEMENT. Subject to
                  the terms and conditions of this Agreement (including, without
                  limitation, the entry into each of the Compound License
                  Agreement and the Amended and Restated License Agreement by
                  Wyeth and DOV) and in partial consideration for the amendments
                  to be made to the Sublicense Agreement as set forth in Article
                  4 below, DOV hereby irrevocably provides its consent to each
                  of Wyeth and Neurocrine for Wyeth to assign to Neurocrine and
                  for Neurocrine to assume all of Wyeth's rights and obligations
                  under the Compound License Agreement. The rights to be so
                  assigned to Neurocrine (i) shall be subject to the rights and
                  licenses granted to DOV under the Compound License Agreement,
                  and (ii) shall

                                       2
<PAGE>

                  not reduce the exclusivity enjoyed by DOV under the Wyeth
                  Patents and Wyeth Know-How (each as defined in the Compound
                  License Agreement) pursuant to the Compound License Agreement
                  beyond that which such exclusivity with respect to such Wyeth
                  Patents and Wyeth Know-How with respect to the Compound was
                  reduced by DOV's grant of rights to Neurocrine under the
                  Sublicense Agreement.

         2.3      CONSENT TO ASSIGN COMPOUND PATENT. Subject to the terms and
                  conditions of this Agreement (including, without limitation,
                  the entry into each of the Compound License Agreement and the
                  Amended and Restated License Agreement by Wyeth and DOV) and
                  in partial consideration for the amendments to be made to the
                  Sublicense Agreement as set forth in Article 4 below, DOV
                  hereby irrevocably provides its consent to each of Wyeth and
                  Neurocrine for Wyeth to assign to Neurocrine and for
                  Neurocrine to assume all of Wyeth's right, title and interest
                  in and to the Compound Patent. The right, title and interest
                  in and to the Compound Patent to be so assigned to Neurocrine
                  (i) shall be subject to the rights and licenses granted to DOV
                  under the Compound License Agreement, and (ii) shall not
                  reduce the exclusivity enjoyed by DOV under the Wyeth Patents
                  and Wyeth Know-How (each as defined in the Compound License
                  Agreement) pursuant to the Compound License Agreement beyond
                  that which such exclusivity with respect to such Wyeth Patents
                  and Wyeth Know-How with respect to the Compound was reduced by
                  DOV's grant of rights to Neurocrine under the Sublicense
                  Agreement.

         2.4      CONSENT TO ASSIGN 2002 CONSENT AGREEMENT. Subject to the terms
                  and conditions of this Agreement (including, without
                  limitation, the entry into each of the Compound License
                  Agreement and the Amended and Restated License Agreement by
                  Wyeth and DOV) and in partial consideration for the amendments
                  to be made to the Sublicense Agreement as set forth in Article
                  4 below, DOV hereby irrevocably provides its consent to each
                  of Wyeth and Neurocrine for Wyeth to assign to Neurocrine and
                  for Neurocrine to assume, subject to the obligations assumed
                  by Neurocrine under the Compound License Agreement, all of
                  Wyeth's rights and obligations under the 2002 Consent
                  Agreement insofar as such rights and obligations relate to the
                  Compound and/or the Compound Patent, it being understood and
                  agreed that Wyeth will at all times remain obligated under the
                  2002 Consent Agreement as and to the extent that Wyeth is the
                  owner or licensor of the ACY Know-How and the ACY Patents (as
                  such terms are defined in the Original License Agreement, but
                  not including the Compound Patent).

         2.5      CONSENT TO GRANT LICENSE TO NEUROCRINE. Subject to the terms
                  and conditions of this Agreement (including, without
                  limitation, the entry into each of the Compound License
                  Agreement and the Amended and Restated License Agreement by
                  Wyeth and DOV) and in partial consideration for the amendments
                  to be made to the Sublicense Agreement as set forth in

                                       3
<PAGE>

                  Article 4 below, DOV hereby irrevocably provides its consent
                  to each of Wyeth and Neurocrine for Wyeth to grant to
                  Neurocrine an exclusive license, with the right to sublicense,
                  under the ACY Know-How and the ACY Patents (as such terms is
                  defined in the Original License Agreement and which terms will
                  be referred to as the "Wyeth Know" and the "Wyeth Patents",
                  respectively, in the Compound License Agreement), with the
                  exception of the Compound Patent, solely for Neurocrine to
                  make, have made, use, import, offer for sale and/or sell
                  pharmaceutical products containing the Compound in the
                  Territory (as such term is defined in the Compound License
                  Agreement). The rights to be so licensed to Neurocrine (i)
                  shall be subject and subordinate to the rights and licenses
                  granted to DOV under the Compound License Agreement, (ii)
                  shall not reduce the exclusivity enjoyed by DOV under the
                  Wyeth Patents and Wyeth Know-How pursuant to the Compound
                  License Agreement beyond that which such exclusivity with
                  respect to such Wyeth Patents and Wyeth Know-How with respect
                  to the Compound was reduced by DOV's grant of rights to
                  Neurocrine under the Sublicense Agreement, and (iii) are to be
                  granted to Neurocrine for purposes of allowing Neurocrine to
                  assume Wyeth's role as licensor of the Wyeth Patents and the
                  Wyeth Know-How and maintaining continuity in the chain of
                  title with respect to the licenses granted thereunder. For the
                  sake of clarity, for so long as the Sublicense Agreement or
                  any license granted under the 2002 Consent Agreement is in
                  effect, Neurocrine's or its Approved Sublicensee's use of the
                  Wyeth Know-How and practice of the Wyeth Patents shall be
                  accomplished through the rights and licenses granted to
                  Neurocrine under the Sublicense Agreement or the 2002 Consent
                  Agreement, respectively.

3.       THE COMPOUND LICENSE AGREEMENT.

         3.1      WAIVER OF CERTAIN RIGHTS. DOV and Neurocrine hereby agree
                  that, effective immediately after the assignment of the
                  Compound License Agreement by Wyeth to Neurocrine and for so
                  long thereafter as the Sublicense Agreement remains in effect,
                  Neurocrine hereby irrevocably waives its rights under, and DOV
                  shall have no further obligations under, Articles 3.0, 8.0 and
                  10.0 and Sections 6.5, 9.2, 14.1, 14.2 and 14.3 of the
                  Compound License Agreement. In the event that the Sublicense
                  Agreement is terminated for any reason, such waiver shall no
                  longer be in effect with respect to any activities occurring
                  after the effective date of such termination.

         3.2      RIGHT OF FIRST REFUSAL. DOV and Neurocrine hereby agree that,
                  effective immediately after the assignment of the Compound
                  License Agreement by Wyeth to Neurocrine, the Compound License
                  Agreement is hereby amended to delete therefrom Article 4.0 in
                  its entirety.

         3.3      PAYMENTS. DOV and Neurocrine hereby agree that effective
                  immediately

                                       4
<PAGE>

                  after the assignment of the Compound License Agreement by
                  Wyeth to Neurocrine and for so long thereafter as the
                  Sublicense Agreement remains in effect or any license granted
                  by Wyeth or DOV to Neurocrine or any sublicensee of Neurocrine
                  remains in effect, the Compound License Agreement is hereby
                  amended by deleting Sections 6.2, 6.3 and 6.4 therefrom in
                  their entirety and inserting in their place, the following:

                           "6.2     DOV shall pay to Wyeth each of the following
                                    Scheduled Payments within thirty (30) days
                                    after the occurrence of the event specified
                                    below for such Scheduled Payment:

<TABLE>
<CAPTION>
                 Event                                Scheduled Payment
                 -----                                -----------------
<S>                                                   <C>
First to occur of the filing of an NDA                   $1,000,000
for the Marketed Product in either the
United States, Japan or within the
European Union

Regulatory approval for the marketing                    $1,500,000
of the Marketed Product within either
the United States, Japan or within the
European Union
</TABLE>

                           6.3      In consideration of the rights and licenses
                                    granted to DOV under Article 2.0 hereof, DOV
                                    shall pay to Wyeth during the term of this
                                    Agreement, on a country-by-country basis,
                                    royalties consisting of two and one-half
                                    percent (2-1/2 %) of Net Sales of Marketed
                                    Product."

                  In the event that the Sublicense Agreement ceases to be in
                  effect for any reason and the licenses granted by Wyeth or DOV
                  to Neurocrine or any sublicensee of Neurocrine pursuant to the
                  2002 Consent Agreement cease to be in effect, the amendment
                  set forth in this Section 3.3 shall no longer be of any force
                  or effect and the Sections 6.2, 6.3 and 6.4 of the Compound
                  License Agreement as they exist prior to the amendment thereto
                  pursuant to this Section 3.3 shall again become effective as
                  of such time.

         3.4      PATENT ENFORCEMENT. DOV and Neurocrine hereby agree that
                  effective immediately after the assignment of the Compound
                  License Agreement by Wyeth to Neurocrine and for so long
                  thereafter as the Sublicense Agreement remains in effect or
                  any license granted by Wyeth or DOV to Neurocrine or
                  Neurocrine's Approved Sublicensee under the 2002

                                       5
<PAGE>

                  Consent Agreement remains in effect, DOV's and Neurocrine's
                  (or Neurocrine's Approved Sublicensee's) rights and
                  obligations with respect to the enforcement of any patent
                  included within the Wyeth Patents (as such term is defined in
                  the Compound License Agreement) shall be governed by the terms
                  and conditions of the Sublicense Agreement (as amended hereby)
                  and that Section 12.3 of the Compound License Agreement shall
                  have no effect. In the event that the Sublicense Agreement is
                  terminated for any reason and the licenses granted by ACY or
                  DOV to Neurocrine or Neurocrine's Approved Sublicensee
                  pursuant to the 2002 Consent Agreement cease to be in effect,
                  the rights and obligations of each of DOV and Neurocrine with
                  respect to the enforcement of any patent included within the
                  Wyeth Patents shall thereafter be governed by Section 12.3 of
                  the Compound License Agreement.

         3.5      TERM OF AGREEMENT. DOV and Neurocrine hereby agree that,
                  effective immediately after the assignment of the Compound
                  License Agreement to Neurocrine, the term of the Compound
                  License Agreement shall be, and, subject to Section 5.6 of
                  this Agreement, DOV's payment obligations to Neurocrine as
                  Wyeth's assignee thereunder shall continue in full force and
                  effect, in each country of the Territory until the later of
                  (a) the final expiration in such country of each patent,
                  including, without limitation, any patent included in the
                  Wyeth Patents and any patent owned or controlled by Neurocrine
                  (including, without limitation, U.S. Patent 6,544,999) which
                  patent would be practiced by the manufacture, use or sale of
                  the Compound or (b) ten (10) years following the first sale of
                  the Licensed Product by DOV or its sublicensee in such
                  country.

4.       AMENDMENTS TO SUBLICENSE AGREEMENT.

         4.1      PATENT ENFORCEMENT. In partial consideration for DOV's
                  agreement to provide the consents set forth in Sections 2.2
                  through 2.5 above, Neurocrine and DOV hereby agree to amend
                  Section 8.2 of the Sublicense Agreement by deleting Section
                  8.2 in its entirety and replacing it with the following:

                           "8.2     Each of DOV and Neurocrine shall promptly
                                    inform the other party of any suspected
                                    infringement by a third party of any patent
                                    included within the Patent Rights and
                                    provide such other party with any available
                                    evidence of such suspected infringement.

                                    Neurocrine, either directly or through its
                                    sublicensee, shall have the right but not
                                    the obligation to institute or initiate any
                                    claim, suit or proceeding against an
                                    infringer or a presumed infringer of any
                                    patent included within the Patent

                                       6
<PAGE>

                                    Rights. Neurocrine, either directly or
                                    through its sublicensee, shall control the
                                    prosecution of any such suit, claim or
                                    proceeding, including, without limitation,
                                    the choice of counsel and any settlement of
                                    any such suit or claim, provided, however,
                                    Neurocrine shall not admit the invalidity of
                                    any patent included within the Patent Rights
                                    pursuant to any such settlement, without
                                    DOV's prior written consent. DOV shall
                                    provide Neurocrine with all reasonable
                                    assistance (other than financial) required
                                    to institute and maintain such proceedings.

                                    In the event that a claim, suit or other
                                    proceeding against an infringer or a
                                    presumed infringer of any patent included
                                    within the Patent Rights is not instituted
                                    or initiated by either Neurocrine or its
                                    sublicensee within six (6) months after DOV
                                    has requested Neurocrine to do so, DOV,
                                    after good faith consultation with
                                    Neurocrine regarding the reasons for
                                    electing not to initiate or institute such
                                    claim, suit or other proceeding, and subject
                                    to Neurocrine's consent, such consent not to
                                    be unreasonably withheld, shall have the
                                    right to institute a claim, suit or
                                    proceeding against such infringer or
                                    presumed infringer. In such event DOV shall
                                    control the prosecution of any such suit,
                                    claim or proceeding, including, without
                                    limitation, the choice of counsel and any
                                    settlement of any such suit or claim,
                                    provided, however, that DOV shall not admit
                                    the invalidity of any patent included within
                                    the Patent Rights pursuant to any such
                                    settlement without Neurocrine's prior
                                    written consent. Neurocrine shall provide,
                                    and shall cause its sublicensee to provide,
                                    DOV with all reasonable assistance (other
                                    than financial) required to institute and
                                    maintain such proceedings.

                                    Any proceeds from any proceeding brought by
                                    or on behalf of Neurocrine or Neurocrine's
                                    sublicensee against an infringer or presumed
                                    infringer as provided in this Section 8.2
                                    shall first be allocated to reimburse each
                                    of DOV, Neurocrine and Neurocrine's
                                    sublicensee for the costs incurred by such
                                    party in connection with such proceedings.
                                    DOV shall be entitled to receive ten percent
                                    (10%) of any amount remaining from such
                                    proceeds and Neurocrine, subject to
                                    Neurocrine's obligations under any agreement
                                    between Neurocrine and its sublicensee with
                                    respect to such proceeds, shall be entitled
                                    to retain the remaining amount of such
                                    proceeds. Any remaining proceeds from any
                                    proceeding brought by or on behalf of DOV
                                    against an infringer or presumed infringer
                                    as

                                       7
<PAGE>

                                    provided in this Section 8.2 shall first be
                                    allocated to reimburse each of DOV and
                                    Neurocrine for the costs incurred by such
                                    party in connection with such proceedings.
                                    DOV shall be entitled to retain ninety
                                    percent (90%) of any amount remaining from
                                    such proceeds and, subject to Neurocrine's
                                    obligations under any agreement between
                                    Neurocrine and its sublicensee with respect
                                    to such proceeds, the remainder shall be
                                    distributed to Neurocrine."

         4.2      TERM. In partial consideration for DOV's agreement to provide
                  the consents set forth in Sections 2.2 through 2.5 above,
                  Neurocrine and DOV hereby agree to amend Section 15.1 of the
                  Sublicense Agreement by deleting Section 15.1 in its entirety
                  and replacing it with the following:

                           "15.1    This Agreement and Neurocrine's payment
                                    obligations hereunder shall continue in full
                                    force and effect in each country of the
                                    Territory until the later of (a) the final
                                    expiration in such country of each patent,
                                    including, without limitation, any patent
                                    included in the Patent Rights and any patent
                                    owned or controlled by Neurocrine
                                    (including, without limitation, U.S. Patent
                                    6,544,999) which patent would be practiced
                                    by the manufacture, use or sale of the
                                    Compound or (b) ten (10) years following the
                                    first sale of the Licensed Product by
                                    Neurocrine or its sublicensee in such
                                    country."

         4.3      GOVERNING LAW. Neurocrine and DOV hereby agree to amend
                  Article 13 of the Sublicense Agreement by replacing in the
                  second line thereof "Delaware" with "New York".

         4.4      PUBLIC COMMUNICATIONS. In partial consideration for DOV's
                  agreement to provide the consents set forth in Sections 2.2
                  through 2.5 above, Neurocrine and DOV hereby agree to amend
                  Section 16.9 of the Sublicense Agreement by adding the
                  following to the end thereof:

                           "In any annual filing made by Neurocrine under the
                           Securities Act of 1934 or any press release issued by
                           or on behalf of Neurocrine or Neurocrine's Affiliates
                           regarding the Compound, Neurocrine shall use its
                           reasonable best efforts to state that the Compound is
                           being developed and/or commercialized under license
                           from DOV. In any public presentation of regarding the
                           Compound made by any employee or representative of
                           Neurocrine or any of Neurocrine's Affiliates,
                           Neurocrine shall use its reasonable efforts to
                           indicate that the Compound is being developed and/or
                           commercialized under license from DOV. Neurocrine
                           shall use its

                                       8
<PAGE>

                           reasonable efforts to request that its sublicensee
                           undertake similar obligations."

5.       OTHER MATTERS.

         5.1      ASSUMPTION OF OBLIGATIONS. Each Party agrees that, upon the
                  assignment by Wyeth to Neurocrine of Wyeth's rights and
                  obligations under the Compound License Agreement, it shall
                  sign and deliver to each of the other Parties an assignment
                  and assumption agreement in the form attached hereto as
                  Exhibit 5.1 duly executed by an authorized officer of such
                  Party.

         5.2      PRESERVATION OF PATENTS. Neurocrine agrees that, upon
                  assignment by Wyeth of the Compound Patent to Neurocrine that
                  Neurocrine shall not, without DOV's prior written consent, (i)
                  allow the Compound Patent to lapse (by reason of failure to
                  pay maintenance fees or annuities or to take any other action
                  necessary to maintain the Compound Patent in full force and
                  effect) or (ii) admit the invalidity of the Compound Patent or
                  take any other action that would result in the invalidity of
                  the Compound Patent.

         5.3      PAYMENT OF LEGAL EXPENSES. Neurocrine agrees that, within five
                  (5) business days after the effective date of this Agreement,
                  it shall pay to DOV those legal fees incurred by DOV in
                  negotiating and entering into the 2002 Consent Agreement,
                  which legal fees amount to Thirty Thousand Nine Hundred Ninety
                  Two Dollars and Seventy-Eight Cents ($30,992.78).

         5.4      NO FURTHER OBLIGATIONS. Each of DOV and Neurocrine agree that,
                  upon the assignment by Wyeth to Neurocrine of Wyeth's rights
                  and obligations under the Compound License Agreement and of
                  Wyeth's right, title and interest in and to the Compound
                  Patent, that Wyeth shall have no further obligations under the
                  Compound License Agreement or with respect to the Compound
                  Patent.

         5.5      EXERCISE OF RIGHTS. Each of DOV and Neurocrine shall exercise
                  and shall cause their respective Affiliates to exercise any
                  and all rights and elections required to preserve the rights
                  granted under the Compound License Agreement and the
                  Sublicense Agreement pursuant to Section 365(n) of the United
                  States Bankruptcy Code (11 USC Section 365(n)).

         5.6      NET PAYMENTS. DOV and Neurcrine hereby agree, that upon the
                  assignment by Wyeth to Neurocrine of Wyeth's rights and
                  obligations under the Compound License Agreement, Neurocrine
                  may subtract from each payment to be made by Neurocrine to DOV
                  under the Sublicense Agreement an amount equal to that portion
                  of such payment that DOV is required to pay to Neurocrine, as
                  Wyeth's assignee, under the Compound License Agreement (prior
                  to such subtraction), provided, however, that for any amount
                  so subtracted by Neurocrine from payments due DOV under

                                       9
<PAGE>

                  the Sublicense Agreement, DOV shall not be required to pay
                  such amounts to Neurocrine, as Wyeth's assignee, under the
                  Compound License Agreement.

6.       MISCELLANEOUS.

         6.1      AMENDMENT. No amendment, modification or supplement of any
                  provision of this Agreement shall be valid or effective unless
                  made in writing and signed by a duly authorized officer of
                  each of the Parties.

         6.2      WAIVER. No provision of the Agreement shall be waived by any
                  act, omission or knowledge of a Party or its agents or
                  employees except by an instrument in writing expressly waiving
                  such provision and signed by a duly authorized officer of the
                  waiving Party. The waiver by either of the Parties of any
                  breach of any provision hereof by the other Party shall not be
                  construed to be a waiver of any succeeding breach of such
                  provision or a waiver of the provision itself.

         6.3      SEVERABILITY. If any clause or portion thereof in this
                  Agreement is for any reason held to be invalid, illegal or
                  unenforceable, the same shall not affect any other portion of
                  this Agreement, as it is the intent of the Parties that this
                  Agreement shall be construed in such fashion as to maintain
                  its existence, validity and enforceability to the greatest
                  extent possible. In any such event, this Agreement shall be
                  construed as if such clause or portion thereof had never been
                  contained in this Agreement, and there shall be deemed
                  substituted therefor such provision as will most nearly carry
                  out the intent of the Parties as expressed in this Agreement
                  to the fullest extent permitted by applicable law.

         6.4      REPRESENTATION BY LEGAL COUNSEL. Each Party hereto represents
                  that it has been represented by legal counsel in connection
                  with this Agreement and acknowledges that it has participated
                  in the drafting hereof and that it has not relied on any
                  statement or action made by any other Party's legal counsel in
                  the discussions regarding this Agreement. In interpreting and
                  applying the terms and provisions of this Agreement, the
                  Parties agree that no presumption shall exist or be implied
                  against the Party who drafted such terms and provisions.

         6.5      NOTICES. Any notices required hereunder shall be sent by
                  registered or certified mail or by an equivalent service
                  capable of verification at the address stated below or such
                  other address as to which the parties may provide in the
                  future.

                                       10
<PAGE>

                  If to Wyeth:

                      Wyeth Pharmaceuticals
                      500 Arcola Road
                      Collegeville, Pennsylvania 19426
                      Attn: Senior Vice President, Global Business Development

                               With a copy to:

                               Wyeth
                               5 Giralda Farms
                               Madison, New Jersey 07940
                               Attn:  General Counsel

                  If to Neurocrine:

                           Neurocrine Biosciences, Inc.
                           10555 Science Center Drive
                           San Diego, California 92121
                           Attn: CEO
                           With copy: General Counsel

                  If to DOV:

                           DOV Pharmaceutical, Inc.
                           433 Hackensack Avenue
                           Hackensack, New Jersey 07601
                           Attn: CEO
                           With copy: General Counsel

         6.6      DESCRIPTIVE HEADINGS. The descriptive headings of this
                  Agreement are for convenience only, and shall be of no force
                  or effect in construing or interpreting any of the provisions
                  of this Agreement.

         6.7      GOVERNING LAW. This Agreement and the 2002 Consent Agreement
                  shall be governed by and interpreted in accordance with the
                  substantive laws of the State of New York, without regard to
                  conflict of law principles thereof.

         6.8      COUNTERPARTS. This Agreement may be executed in any number of
                  counterparts each of which shall be an original and all
                  originals of which shall be deemed a single instrument.

         6.9      ENTIRE AGREEMENT. This Agreement represents the full
                  understanding between the Parties with respect to the subject
                  matter hereof and cancels and supersedes any and all prior
                  negotiations, correspondence, understandings and agreements,
                  whether oral or written, among the Parties respecting the
                  subject matter hereof. Notwithstanding the foregoing,

                                       11
<PAGE>

                  except as expressly stated herein with respect to the
                  amendments to be made to the Compound License Agreement, the
                  amendments to be made to the Sublicense Agreement, and the
                  rights and obligations of Wyeth under each of the Compound
                  License Agreement and the 2002 Consent Agreement, this
                  Agreement shall have no effect on the Compound License
                  Agreement, the Sublicense Agreement or the 2002 Consent
                  Agreement, which agreements shall continue in full force and
                  effect as so amended.

         6.10     INDEPENDENT CONTRACTORS. This Agreement shall not constitute
                  any Party as the joint venturer, legal representative or agent
                  of any other Party hereto and no Party hereto shall have the
                  right or authority to assume or create any obligation on the
                  part of any other Party hereto.

IN WITNESS WHEREOF, THE PARTIES HERETO HAVE CAUSED THIS AGREEMENT TO BE EXECUTED
BY THEIR DULY AUTHORIZED REPRESENTATIVES.

WYETH HOLDINGS CORPORATION

/s/ Robert A. Dougan
By: Robert A. Dougan
Title: Senior Vice President

NEUROCRINE BIOSCIENCES, INC.

/s/ Gary A. Lyons
By: Gary A. Lyons
Title: President and CEO

DOV PHARMACEUTICAL, INC.

/s/ Robert Horton
By: Robert Horton
Title: Vice President and General Counsel

                                       12<PAGE>
                                                                    EXHIBIT 10.3

                                LICENSE AGREEMENT

         THIS AGREEMENT (the "Agreement') is entered into on this 25th day of
February, 2004 by and between DOV PHARMACEUTICAL, INCORPORATED, a corporation
organized and existing under the laws of the Delaware, having its registered
offices at Continental Plaza, 433 Hackensack Avenue, Hackensack, New Jersey
07601, (hereinafter DOV) and WYETH HOLDINGS CORPORATION (formerly known as
"American Cyanamid Company"), a corporation organized under the laws of the
State of Maine, U.S.A., having its principal place of business at 5 Giralda
Farms, Madison, New Jersey 07940, U.S.A., (hereinafter Wyeth).

                                   WITNESSETH:

         WHEREAS, DOV and Wyeth entered into that certain License Agreement
dated May 29, 1998 (as previously amended, the "Original License Agreement")
pursuant to which Wyeth granted to DOV a worldwide exclusive license for a group
of four (4) specified compounds;

         WHEREAS, on even date herewith DOV and Wyeth entered into an Amended
and Restated License Agreement, which agreement amends and restates the Original
License Agreement so as to remove from such agreement the rights and licenses
granted to DOV and the other rights and obligations of each of the parties
thereunder, in each case, which rights, licenses and obligations relate to the
compound designated as CL 285,489 (also known as Indiplon);

         WHEREAS, DOV and Wyeth now desire to enter into this license agreement
to provide for the grant of a worldwide, exclusive license to DOV under certain
intellectual property rights of Wyeth for the development and commercialization
of CL 285,489;

         WHEREAS, Wyeth possesses intellectual property rights relating to the
chemical compound listed in Schedule 1 attached hereto and made a part hereof
and to pharmaceutical products to be processed from the aforesaid compound.

                                       1
<PAGE>

         WHEREAS, Wyeth designates Wyeth Pharmaceuticals, an Affiliate of Wyeth,
with principal offices at 500 Arcola Road, Collegeville, Pennsylvania 19426,
U.S.A., as the correspondent and contact for day-to-day business regarding the
compounds that appear in Schedule 1. All correspondence and contacts shall be
with Wyeth Pharmaceuticals.

         WHEREAS, DOV is interested to develop as well as manufacture, have
manufactured by, use, and sell pharmaceutical products containing CL 285,489
worldwide under a license that Wyeth is willing to grant.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants and agreements set forth herein, the parties hereto agree as follows:

ARTICLE 1.0 DEFINITIONS

1.1      "Effective Date" means the date upon which this License Agreement is
         executed by both parties.

1.2      "Product" means the compound listed in Schedule 1.

1.3.     "Marketed Product" means the pharmaceutical preparation in finished
         form containing Product suitable for human administration, whether
         alone or in combination with other active ingredients.

1.4      "Wyeth Patents" means all patents, certificates of invention, and
         applications covering the Product. Such Wyeth Patents are listed in
         Exhibit A of this License Agreement.

1.5      "Wyeth Know-How" means all information, patentable or otherwise,
         developed, applied, or acquired by Wyeth as of May 22, 1997 relating to
         the production or development of the Product that is reasonably useful
         or necessary to develop or manufacture Product.

                                       2
<PAGE>

1.6      "Wyeth's Place of Payment" means 500 Arcola Road, Collegeville,
         Pennsylvania 19426.

1.7      "Affiliate" means with respect to a party, any other business entity
         that directly or indirectly controls, is controlled by, or is under
         common control with, such party. A business entity or party shall be
         regarded as in control of another business entity if it owns, or
         directly or indirectly controls, at least fifty percent (50%) of the
         voting stock or other ownership interest of the other business entity,
         or if it directly or indirectly possesses the power to direct or cause
         the direction of the management and policies of the other business
         entity by any means whatsoever.

1.8      "Net Sales" shall mean the gross amount invoiced for the Marketed
         Product sold by DOV and/or its Affiliates or their sublicensees
         (including any further sublicensees), less:

         (i)      transportation charges or allowances, if any, included in such
                  price;

         (ii)     trade, quantity or cash discounts, service allowances and
                  broker's or agent's commissions but not salaries, commissions,
                  bonuses or other incentive pay to in-house sales or other
                  personnel, if any, allowed or paid;

         (iii)    credits or allowances, if any, given or made on account of
                  price adjustments, returns, bad debts, off-invoice promotional
                  discounts, rebates, and any all Federal, state or local
                  government rebates whether in existence now or enacted at any
                  time during the term of this Agreement (e.g., HCFA or Medicaid
                  rebates), rejections, recalls or destruction requested or made
                  by an appropriate government agency; and

         (iv)     any tax, excise or governmental charge upon or measured by the
                  sale, transportation, delivery or use of the Marketed Product;

         provided that Net Sales shall in no event be less than 80% of Gross
         Sales.

         In the case of discounts on "bundles" of products which include the
         Marketed Product, DOV, its Affiliates and its sublicensees (including
         further sublicensees) may, with notice

                                       3
<PAGE>

         to Wyeth, calculate Net Sales as set forth above discounting the bona
         fide list price of the Marketed Product by the average percentage
         discount of all products of the selling party and/or its Affiliates or
         sublicensees in a particular "bundle", calculated as follows:

                  Average percentage
                  discount on a                      = (1-A/B) x 100
                  particular "bundle"

         where A equals the total discounted price of a particular "bundle" of
         products, and B equals the sum of the undiscounted bona fide list
         prices of each unit of every product in such "bundle". DOV shall
         provide Wyeth documentation, reasonably acceptable to Wyeth,
         establishing such average discount with respect to each "bundle". Where
         the Marketed Product is also sold other than in bundled form, the
         average discount as calculated above shall be applied to the
         undiscounted list price of the Marketed Products in the "bundle". If
         the Marketed Product is not sold separately and no bona fide list price
         exists for the Marketed Product, the parties shall negotiate in good
         faith an imputed list price for the Marketed Product, and the average
         discount as calculated above with respect thereto shall be applied to
         such imputed list price.

1.9      "Territory" means all countries of the world.

1.10     "Scheduled Payments" means those lump sums payable at the time of the
         achievement of specific developmental activities during the development
         period through actual commercial introduction of a Product following
         regulatory approval.

1.11     As used in this e Agreement, the singular includes the plural and the
         plural includes the singular, wherever appropriate by fact or by
         context.

                                       4
<PAGE>

ARTICLE 2.0 LICENSE GRANT

2.1      Effective as of May 29, 1998, Wyeth hereby grants DOV an exclusive
         license under Wyeth Patents and Wyeth Know-How to make, have made, use,
         import, offer for sale and/or sell Marketed Product in the Territory.

2.2      Subject to Wyeth's right of first refusal provided for in Article 4.0,
         and the provisions in Article 5.0; DOV shall have the right to grant
         sublicenses under the License provided for in Article 2.1.

ARTICLE 3.0 DEVELOPMENTAL ACTIVITIES

3.1      While this Agreement is in effect, DOV shall use reasonable efforts to
         develop and commercialize the Product, either through itself or through
         a third party commercial partner. Such activities include negotiating
         the terms of a sublicense agreement with a third party.

3.2      DOV may disclose unpublished Wyeth Patents and Wyeth Know-How to a
         third party, bound under an obligation of confidentiality which is
         substantially the same as the obligation provided for in Article 7 of
         this License Agreement, to the extent necessary to negotiate a
         sublicense, and thereafter to develop and commercialize the Product.

3.3      On a quarterly basis, DOV shall provide Wyeth with a written report
         outlining its developmental activities during that quarter.

ARTICLE 4.0 WYETH RIGHT OF FIRST REFUSAL

4.1      Prior to its entering into a sublicense agreement with a third party
         with respect to Product, DOV shall present, in writing, to Wyeth the
         bona fide proposed terms and conditions of said sublicense agreement.
         Following receipt by Wyeth of said terms and conditions, Wyeth shall
         have sixty (60) days to notify DOV if it intends to enter into a
         development agreement with DOV, the terms of which would exceed those
         proposed by a third party by 10% relative to Scheduled Payments and
         royalties. So as to permit Wyeth to reach

                                       5
<PAGE>

         such decision, DOV shall provide to Wyeth all relevant data and
         information regarding Product available to DOV, simultaneously with its
         providing to Wyeth the terms and conditions offered by the said third
         party.

4.2      Upon Wyeth's providing DOV with notification of its intent to enter
         into an agreement with DOV pursuant to Article 4.1, the parties will
         promptly negotiate said agreement embodying Wyeth's offer under Article
         4.1 and this License Agreement shall terminate upon the effective date
         of said agreement, solely with regard to the Product(s) elected by
         Wyeth under Article 4.1 and contained in said agreement.

4.3      If Wyeth does not notify DOV of its intention to enter into an
         agreement with DOV pursuant to Articles 4.1 and 4.2, hereinabove,
         within the agreed upon period, DOV shall be free to enter into a
         sublicense agreement with the third party under the terms presented to
         Wyeth, or better.

4.4      In the event that DOV files a New Drug Application (NDA) in the USA, or
         a foreign equivalent thereof in Europe or Japan, but has not yet
         entered into a license agreement with a third party for Product, DOV
         shall provide Wyeth with a copy of the NDA ( or the foreign equivalent
         thereof as filed together with its English translation) for evaluation
         by Wyeth. If Wyeth shall express an interest in marketing the Product,
         then the parties shall enter into good faith negotiations relating to
         the possibility of Wyeth's obtaining marketing rights to the Product.

ARTICLE 5.0 SUBLICENSE AGREEMENTS

5.1      If DOV grants a sublicense to a third party with regard to Product
         under this Agreement, such sublicense agreement shall provide for DOV
         to receive Scheduled Payments and royalty payments based on Net Sales
         of Marketed Product.

                                       6
<PAGE>

ARTICLE 6.0 PAYMENTS

6.1      Within thirty (30) days after the Effective Date of the Original
         License Agreement, DOV shall pay Wyeth the fee as indicated below in
         this paragraph 6.1 for exercising its Option rights with regard to each
         Product. Such fee shall be non-refundable and non-creditable against
         any other payments due Wyeth pursuant to this Agreement:

         CL 285,489         $  50,000

         Wyeth acknowledges that the fee provided for in this Section 6.1 has
         been received.

6.2      If DOV enters into a sublicense agreement with a third party before the
         filing of an NDA (or the foreign equivalent thereof in Europe or Japan)
         for a Product, DOV shall, subject to the minimum conditions set forth
         in paragraph 6.4 of this Agreement, pay Wyeth during the term of this
         Agreement 35% of all remuneration, excluding all adequately documented
         future research and development payments, whether tangible or
         intangible, including all Scheduled Payments within 30 days of receipt
         by DOV from such sublicensee and one-third of all other royalties and
         profits, whether tangible or intangible, within 30 days of receipt by
         DOV derived from the final sale to the trade of Marketed Product by DOV
         or its sublicensee, as the case may be.

6.3      If DOV enters into a sublicense agreement with a third party after the
         filing of an NDA (or the foreign equivalent thereof in Europe or Japan)
         for a Product, DOV shall, subject to the minimum conditions set forth
         in paragraph 6.4 of this Agreement, pay Wyeth during the term of this
         Agreement 25% of all remuneration, whether tangible or intangible,
         including Scheduled Payments within 30 days of receipt by DOV from such
         sublicensee; and 25% of all other royalties and profits; whether
         tangible or intangible, within 30 days of receipt by DOV derived from
         the final sale to the trade of Marketed Product by DOV or its
         sublicensee, as the case may be.

                                       7
<PAGE>

6.4      Notwithstanding any other provision of this Agreement, Wyeth shall in
         no event receive Scheduled Payments and once the Product has been
         commercialized, royalties on sales of Marketed Product to the trade by
         DOV or its third-party sublicense with respect to each Product listed
         in Schedule 1, which Scheduled Payments, in the aggregate, and
         royalties are less than the amounts below indicated in this paragraph.
         For the sake of clarity, in the event the portion of the first
         Scheduled Payment received by DOV from a sublicensee which portion is
         payable by DOV to Wyeth in accordance with Section 6.2 above, is less
         than the amount indicated below in this paragraph, DOV shall pay to
         Wyeth the minimum amount set forth below at such time and that portion
         of such minimum amount that is in excess of the amount payable by DOV
         to Wyeth pursuant to Section 6.2 above as the result of DOV's receipt
         of such Scheduled Payment from its sublicensee, shall be credited
         against any further Scheduled Payments due from DOV to Wyeth under this
         Agreement.. The Scheduled Payments due Wyeth for the Schedule 1
         compound shall be paid pursuant to the 30-day period specified in
         paragraphs 6.2 and 6.3 if received by DOV from third parties; but in
         the event that DOV achieves the filing of an NDA, or its equivalent in
         the United States, Europe, or Japan for a Product without assistance of
         a third party, DOV shall remit to Wyeth the aggregate minimum Scheduled
         Payments set forth below no later than 30 days following the
         achievement of such Regulatory filing.

<TABLE>
<CAPTION>
AGGREGATE MINIMUM SCHEDULED                              MINIMUM ROYALTY DUE TO
PAYMENT FOR EACH PRODUCT DUE WYETH                         WYETH ON NET SALES
----------------------------------                         ------------------
<S>                  <C>                                 <C>
CL 285,489           $2.5 Million                                 2.5%
</TABLE>

         Provided however if marketing exclusivity in any country of the
         Territory is lost to DOV or its sublicensee prior to the expiration of
         this Agreement in such country, the parties shall meet to discuss
         whether any modification to these terms is appropriate.

6.5      DOV shall keep and shall obligate its sublicensees to keep accurate and
         complete records of all sales of Product and Marketed Product in
         accordance with generally

                                       8
<PAGE>

         accepted accounting principles and practices. In any agreement between
         DOV and a third party, DOV shall obligate such third party to allow
         routine audits by Wyeth of such third party's records relating to the
         Product and Marketed Product and shall further require such third party
         to likewise obligate any additional third party that enters into an
         agreement with the third party relating to the Product and Marketed
         Product to allow routine audits by Wyeth of such additional third
         party's records relating to the Product and Marketed Product. Wyeth, no
         more than one time per calendar year for each of DOV or any third party
         so audited, may conduct, at its own expense, at reasonable times during
         normal business hours, through an accountant designated by Wyeth and
         acceptable to DOV (and its sublicensees and their sublicensees, as
         appropriate), an audit of the accounts contemplated above, as well as
         any supporting instruments and documents, and may make copies of and
         extracts from such records for the sole purpose of ascertaining or
         verifying the correctness of the amounts remitted by DOV hereunder.
         Such accountant shall be required by DOV or any sublicensee to enter
         into a reasonably acceptable confidentiality agreement, and in no event
         shall such accountants disclose to Wyeth or DOV any information other
         than information relating to or supporting the accuracy of the payments
         due from DOV hereunder (and, except to the extent necessary to support
         sales data using bundles, in no event information that relates to
         products other than the Product or Marketed Product). Each such audit
         shall be limited to the records and accounts pertaining to the year on
         which the audit is conducted and the immediately preceding 5 calendar
         years. Results in the form of a report of such audit shall be made
         available by Wyeth to DOV and to any third party that is the subject of
         the audit. Should such audit reveal any discrepancies between reports
         made by DOV or its sublicensees and the audit exceeding five percent
         (5%) in favor of DOV or any third party that is audited, then DOV shall
         pay in full the costs of such audit requested by Wyeth; otherwise,
         Wyeth shall bear the costs in full for the audit of the records of DOV,
         its Affiliates, or its sublicensees. In the event DOV, its Affiliates
         or sublicensees (including further sublicensees) conducts an audit of
         any sublicensee selling the Product and Marketed Product, DOV shall
         provide or shall cause such Affiliate or sublicensee to provide to
         Wyeth a copy of each audit report generated in connection therewith.

                                       9
<PAGE>

6.6      Royalty payments shall be due within the shorter period of thirty (30)
         days following receipt thereof by DOV or sixty (60) days of the end of
         each calendar quarter on Net Sales made in that quarter and shall be
         paid at Wyeth's Place of Payment. Royalties shall accrue in the
         currency of the country in which the sale of Marketed Product is made,
         and if different from U. S. dollars shall be converted into such
         currency using the exchange rate appearing in the Wall Street Journal
         applicable for the last day of the calendar quarter during which the
         royalties accrued.

6.7      All taxes, assessments, fees. and charges, if any, levied under income
         tax laws or regulations with respect to payments due Wyeth hereunder
         shall be for the account of Wyeth and if required by law to be withheld
         and paid to the applicable jurisdiction, may be deducted by DOV from
         such payments due to Wyeth. Receipts for all such deducted taxes,
         assessments, fees and charges paid by DOV to the taxing authorities
         shall be secured by DOV and sent to Wyeth.

6.8      In case of any delay in payment by DOV to Wyeth not occasioned by force
         majeure, interest at the rate of one percent (1%) per month, assessed
         from the thirty-first day after the due date of the said payment, shall
         be due Wyeth without any special notice.

ARTICLE 7.0 CONFIDENTIALITY

7.1      If during the performance of this Agreement, one party hereto wishes to
         disclose information to another that it considers confidential, and if
         the receiving party is willing to accept such information, then such
         information may not be subsequently disclosed by the receiving party to
         a third party, other than as provided in this Agreement, without the
         written permission of the disclosing party. The parties to this
         Agreement agree to hold in confidence all information and all
         knowledge, know-how, practices, process, or other information disclosed
         or submitted in writing or in other tangible form that is considered to
         be confidential for a period of five (5) years from the date of such
         disclosure, except:

                                       10
<PAGE>

         (a)      information that, at the time of disclosure, is in the public
                  domain;

         (b)      information that, after disclosure, is published or otherwise
                  becomes part of the public domain through no fault of the
                  receiving party;

         (c)      information that was in the possession of the receiving party
                  at the time of disclosure;

         (d)      information that is developed by or on behalf of the receiving
                  party independently of any disclosure to it by the disclosing
                  party hereunder; or

         (e)      information that is provided to the receiving party by a third
                  party with the right to so provide.

ARTICLE 8.0 ADVERSE EXPERIENCE

8.1      DOV shall keep (and DOV shall cause its sublicensees to keep under
         terms and conditions equal to those set forth in this Article 8) Wyeth,
         during the term of this Agreement, promptly and fully informed of all
         pharmaceutical, toxicological and clinical findings relating to adverse
         experience of the Product or Marketed Product.

8.2      DOV undertakes to notify Wyeth promptly with written confirmation by
         immediate telecopy of any information concerning any serious adverse
         event as defined by C.I.O.M.S. or the F.D.A. or by the Ministry of
         Health & Welfare in Japan, as applicable, reasonably associated with
         clinical studies or attributed to the use or application of the Product
         and Marketed Product. In any event the above notification shall be made
         within two working days after DOV should first learn or be advised of
         all relevant information with respect to such adverse event.

8.3      DOV shall also forward regularly (and usually every six months unless
         the parties agree on another period) to Wyeth any information on all
         other adverse effects or any difficulty

                                       11
<PAGE>

         associated with the clinical use, studies, investigations, tests and
         prescription of the Product or Marketed Product.

8.4      DOV shall provide upon request the information on patient exposure:
         estimated patient days of exposure.

8.5      DOV shall inform Wyeth, without delay, of any governmental action,
         correspondence or reports to or from governmental authorities that may
         affect the situation of the Product or Marketed Product and furnish
         Wyeth with copies of any relevant documents relating thereto.

ARTICLE 9.0 REPRESENTATIONS AND WARRANTIES

9.1      Wyeth hereby represents and warrants that it has the right to grant DOV
         the license under Article 2 of this Agreement, and that, as of the
         effective date of the Original License Agreement, Wyeth is not aware of
         any lawsuit, opposition or action of any kind questioning or contesting
         the validity of the Wyeth Patents. Notwithstanding the foregoing, Wyeth
         makes no other warranties, expressed or implied, and Wyeth does not
         warrant, nor does it entitle any agent, officer, employee or
         representative of Wyeth to warrant validity, enforceability, efficacy,
         merchantability, fitness for a particular purpose or otherwise with
         respect to any Product, Marketed Product or Wyeth Patent as the case
         may be.

9.2      DOV is fully cognizant of Good Laboratory Practices ("GLP") and Good
         Manufacturing Practices ("GMP") and shall manufacture or have
         manufactured Product and Marketed Product in a manner that fully
         complies with GLP and GMP.

ARTICLE 10.0 INDEMNIFICATION, LIABILITY AND INSURANCE

10.1     DOV shall at all times during the term of this Agreement, and
         thereafter, indemnify, defend and hold Wyeth and all its Affiliates and
         their respective directors, officers, partners, employees, servants and
         agents harmless from and against any and all claims

                                       12
<PAGE>

         and expenses, including without limitation legal expenses, court costs,
         and reasonable attorney's fees, arising out of or relating to the death
         of or actual or alleged injury to any person or damage to any third
         party's property, and from and against any other claim, proceeding,
         demand, expense, cost and liability of any kind whatsoever
         (collectively "liabilities") resulting from, arising out of or related
         to Product or Marketed Product.

10.2     DOV shall take all necessary steps, at its own costs, and shall so
         obligate its sublicensee to properly maintain insurance policies to
         cover all liabilities to any third party that might be incurred,
         directly or indirectly as a result of its participation in the
         performance of this Agreement.

10.3     DOV shall maintain (and shall cause its sublicensee to maintain)
         product liability insurance that may include funded self-insurance
         reserves with respect to the development, manufacture and sale of the
         Product and Marketed Product in such amount as customary in the
         industry. DOV (and its sublicensee) shall maintain such insurance for
         so long as it continues to develop, manufacture or sell any Product and
         Marketed Product and thereafter for so long as required to cover such
         manufacture or sales.

         DOV (and its sublicensee) shall name Wyeth as an additional insured on
         its insurance policy. Upon execution of the Original License Agreement
         DOV has supplied and during the term of this Agreement, upon Wyeth's
         request, DOV shall supply Wyeth with evidence of such coverage, and
         undertakes to communicate to Wyeth during the term of this Agreement
         any modifications to such coverages.

ARTICLE 11.0 USE OF NAMES/ TRADEMARKS/PUBLICITY

11.1     Neither party shall use the name of the other party in any advertising
         or other form of publicity without the written permission of the other.

11.2     By virtue of this License Agreement, DOV shall not acquire any right to
         use trademarks, tradedress or other indicia of origin belonging to
         Wyeth, or any of its Affiliates.

                                       13
<PAGE>

11.3     The timing and content of any press release or other public
         communications relating to this Agreement and the transactions
         contemplated herein shall, except as otherwise required by law, be
         determined jointly by Wyeth and DOV.

ARTICLE 12.0 PATENT INFRINGEMENTS

12.1     Wyeth shall be responsible for the filing, prosecution and maintenance
         of the Wyeth Patents. Wyeth shall not allow any issued Patent included
         within the Wyeth Patents and listed or Exhibit A attached hereto to
         lapse (by reason of failure to pay maintenance fees or annuities or to
         take any other action necessary to maintain such patent in full force
         and effect) or admit the invalidity thereof prior to the mutual
         expiration date thereof without DOV"s prior consent.

12.2     In case any actions, claims, demands, suits or other legal proceedings
         are brought or threatened to be brought against DOV by a third party
         for infringement of such third party's patent(s) relating to Product
         per se, by virtue of DOV's manufacture, use, sale or offer for sale of
         the Product or Marketed Product hereunder, DOV shall notify Wyeth
         forthwith of the threat or existence of such actions with sufficient
         evidence thereof to enable the parties to prepare an appropriate
         defense. strategy. The parties shall consult together as to the action
         to be taken and as to how the defense will be handled. DOV shall be
         responsible for all defense costs.

         DOV undertakes not to make any admission of liability to a claimant or
         plaintiff or his or her legal representative or insurer and not to sign
         any agreement in respect of such proceedings without Wyeth's previous
         written consent not to be unreasonably withheld.

         When DOV, because of the settlement with Wyeth's consent of the claimed
         infringement, or a final unappealable or non-appealed judgment of a
         court of competent jurisdiction, is required to make payments to one or
         more third parties to obtain a license without which the marketing of
         the Marketed Product could not be made in a given country, DOV may

                                       14
<PAGE>

         deduct such payments from the royalty payments due to Wyeth hereunder,
         provided however that in no event shall the royalty rate be reduced by
         more than fifty percent (50%) of that which would otherwise be due
         Wyeth.

12.3     DOV shall promptly inform Wyeth of any suspected infringement of any of
         Wyeth Patents by a third party and provide Wyeth with any available
         evidence of such suspected infringement.

         Wyeth shall have the right but not the obligation to institute any
         claim, suit or proceeding against an infringer or a presumed infringer
         to protect and defend Wyeth Patents. Wyeth shall control the
         prosecution of any such suit or claim, including without limitation the
         choice of counsel and shall settle or dispose of any such suit or
         claim. DOV shall provide Wyeth with all reasonable assistance (other
         than financial) required to institute and maintain such proceedings. In
         the event Wyeth so elects, Wyeth shall bear the entire costs of such
         prosecution and shall be entitled to retain, after deducting the costs
         and expenses borne by Wyeth in prosecuting the claim of infringement,
         ninety percent (90%) of the amount of any recovery, court award or
         settlement.

         DOV shall not institute any negotiations or legal proceedings with
         respect to any such infringement without prior written consent of
         Wyeth, but shall have the right to institute infringement proceedings
         against a third party in the event that Wyeth elects not to do so. In
         such event, DOV shall bear the entire costs and expenses of such
         proceedings. Wyeth shall provide DOV with all reasonable assistance
         (other than financial) required to institute and maintain such
         proceedings. In such event, DOV shall be entitled to retain ninety
         percent (90%) of the proceeds of any such recovery, after first
         deducting the costs and expenses borne by DOV in initiating and
         maintaining such infringement action and shall pay the remainder to
         Wyeth.

                                       15
<PAGE>

ARTICLE 13.0 DURATION AND TERMINATION

13.1     This Agreement shall be binding on the parties as of the day of its
         execution but shall have no force or effect until either the parties
         determine that notification under Title II of the Hart-Scott-Rodino
         Antitrust Improvements Act of 1976, 15 U.S.C. 18a, and the regulations
         promulgated thereunder, 16 C.F.R. 801.1 et seq., is not required or if
         the parties determine that such notification is required, the waiting
         period shall have expired or been terminated. If a notification filing
         is required, the parties shall, at their own expense, prepare and make
         all appropriate filings. The parties shall cooperate in the antitrust
         clearance process and hereby agree to furnish promptly to the FTC and
         the Antitrust Division of the Department of Justice such additional
         information reasonably requested by them in connection with such
         filings. In the event that the waiting period has not expired or been
         terminated within six (6) months after the date of signature of this
         agreement by both parties, the parties shall revert to their status
         before signing and this agreement shall be of no force and effect,
         except for Articles 7, 10, and 11 which shall survive pursuant to their
         terms. Thereafter, the Agreement shall continue in full force and
         effect in each country of the Territory until the later of expiration
         of the Wyeth Patents in such country or a period of ten (10) years
         following the launch of such Marketed Product by DOV or its
         sublicensee(s) in each country of the Territory.

13.2     Upon expiration of this Agreement with respect to each country of the
         Territory, DOV shall be deemed to have a fully-paid, royalty-free
         license with the right to make or have made, use or sell Product and
         Marketed Product as well as to freely utilize all data generated
         hereunder or received from Wyeth by DOV without DOV's having further
         obligation to Wyeth, except for maintaining confidentiality as required
         by Article 7.1 of this Agreement.

13.3     DOV shall be free to terminate this entire Agreement and surrender and
         return to Wyeth all rights acquired by DOV hereunder in its own
         discretion at any time upon 90 days' prior written notice at which time
         all license rights granted hereunder shall come to an end.

                                       16
<PAGE>

13.4     In the event that a party hereto shall be presumed by the other to have
         breached any material condition herein contained, the complaining party
         shall be required to provide a formal written notice of such presumed
         breach, requesting rectification within a sixty-day period from the
         date of receipt of such notice. The party presumed to be in breach of
         this Agreement shall either submit a commercially reasonable plan for
         rectification within 45 days of receipt of notice (if the breach cannot
         be rectified within the sixty-day period), or take appropriate steps to
         remedy the breach if capable of remedy within such period. If within
         the said sixty-day period neither the aforesaid plan has been
         submitted, nor the breach cured, the party alleging breach shall then
         be entitled to terminate this Agreement, thereby surrendering all
         rights granted hereunder, by written notice to the other party, such
         termination having immediate effect.

13.5     This Agreement may be terminated at once by Wyeth giving notice to DOV
         if DOV is insolvent or has committed an act of bankruptcy or an order
         is made or resolution passed for the winding up of either party.

13.6     In the event this Agreement is terminated prior to its full term
         pursuant to paragraph 13.3 by DOV or pursuant to paragraphs 13.4 or
         13.5 by Wyeth, DOV shall within thirty (30) days of such event transfer
         to Wyeth all information, data and know-how of any kind relating to the
         Product and shall authorize the transfer of all governmental approvals
         for the Product to Wyeth, in addition to DOV's right derived from all
         license agreements between DOV and its third party partners relative to
         Product and Marketed Product.

ARTICLE 14.0 REPORTS AND NOTICES

14.1     Upon Wyeth's request, DOV shall provide Wyeth an annual report
         summarizing the stage of development relating to the Product. Such
         report shall be provided within thirty (30) days of each anniversary of
         the signing of this Agreement.

                                       17
<PAGE>

14.2     DOV shall notify Wyeth in writing within fifteen (15) days after
         achieving an event that would require that a Scheduled Payment be paid
         by a third party to DOV, or by DOV to Wyeth, with respect to the
         Product.

14.3     Not later than sixty (60) days following the end of each quarter, DOV
         shall provide Wyeth with a report summarizing the Net Sales of Marketed
         Product in each country in the Territory made by DOV or a third party
         sublicensee of DOV. Such reporting shall begin following the first sale
         of Marketed Product in the Territory.

14.4     Any notices or reports required or permitted to be given under this
         Agreement shall be sent by certified or registered mail, or by an
         equivalent service that provides verification of delivery, return
         receipt requested to the respective party at the address stated below
         or such address as to which the parties are subsequently appropriately
         notified:

         If to Wyeth:  Wyeth
                       500 Arcola Road
                       Collegeville, PA 19426
                       Attn: Senior Vice President, Global Business Development

         If to DOV:    DOV Pharmaceutical, Inc.
                       Continental Plaza
                       433 Hackensack Avenue
                       Hackensack, NJ  07601
                       Attn: President

ARTICLE 15.0 ASSIGNMENT

15.1     This Agreement shall be binding upon and inure to the benefit of the
         parties hereto and the successors to substantially the entire business
         and assets of the respective parties hereto. Notwithstanding the
         foregoing, any party may void this Agreement if the Agreement is
         assigned for the benefit of a creditor. This Agreement shall not be

                                       18
<PAGE>

         assignable by either party, except to an Affiliate, without the prior
         written consent of the other party; any other attempted assignment is
         void.

ARTICLE 16.0 APPLICABLE LAW

16.1     This Agreement shall be governed by and construed according to the laws
         of the State of New York, USA.

ARTICLE 17.0 FORCE MAJEURE

17.1     None of the parties shall be responsible for failure or delay in the
         performance of any of its obligations hereunder due to Force Majeure.
         Force Majeure shall mean any circumstance that, due to an event or a
         legal position beyond the party's reasonable control, renders
         impossible the fulfillment of any of the party's obligations hereunder,
         such as, but not limited to, acts of God, acts, regulations, or laws of
         any government, war, civil commotion, destruction of facilities or
         materials by fires, earthquakes, or storms, labor disturbances,
         shortages of public utilities, common carriers, or raw materials, or
         any other cause, or causes of similar effects, except, however, any
         economic occurrence. During any such case of Force Majeure, this
         Agreement shall not be terminated, but only suspended and the party so
         affected shall continue to perform its obligations as soon as such case
         of Force Majeure is removed or alleviated.

ARTICLE 18.0 MISCELLANEOUS

18.1     This Agreement and the Schedules hereto constitute the full
         understanding and entire agreement between the parties and supersedes
         and replaces any and all prior oral or written understandings and
         agreements with respect to the subject matter hereof including, without
         limitation, the Original License Agreement. Notwithstanding the
         foregoing, this Agreement shall not be deemed to have modified (i) the
         Consent and Agreement entered into by Wyeth, DOV and DOV's sublicensee,
         Neurocrine Bioscience's Inc. ("Neurocrine"), on December 13, 2002, (ii)
         the Consent Agreement and

                                       19
<PAGE>

         Amendment entered into by Wyeth, DOV and Neurocrine on February __,
         2004, or (iii) the Sublicense and Development Agreement entered into by
         DOV and Neurocrine June 30, 1998, each of which shall remain in full
         force and effect in accordance with the terms and conditions thereof as
         amended from time to time. This Agreement shall not be effective until
         duly signed by officers of both Wyeth and DOV. No terms, conditions,
         understandings or Agreements purporting to modify, amend or vary this
         Agreement shall be binding unless made in writing and signed by the
         parties hereto. It is mutually agreed that no party has relied upon any
         representations or statements of any third party except as stated
         herein.

18.2     The invalidity or unenforceability of an Article or any part of an
         Article of this Agreement in any jurisdiction shall not cause the
         invalidity of the whole Agreement as to such jurisdiction, and shall
         not affect the validity or enforceability of such Article or such part
         of an Article in any other jurisdiction. The parties shall replace any
         Article or part of an Article found invalid or unenforceable by
         alternative provisions which shall be as similar as possible in their
         conditions with regard to their spirit and commercial effect. If this
         Agreement in any jurisdiction is found to be invalid or unenforceable,
         the parties shall replace it by an alternative Agreement which shall be
         as similar as possible in its conditions with regard to its spirit and
         commercial effect.

18.3     The failure of either party on any occasion to require the performance
         by the other of any provision hereof shall in no manner affect the
         right of such party to enforce the same on a subsequent occasion. The
         waiver by either party of any breach of any provision hereof shall at
         no time be construed to be a waiver of any succeeding breach of that or
         any other provision or a waiver of the provision itself.

18.4     This Agreement shall not constitute either party as the joint venturer,
         legal representative or agent of the other party for any purpose
         whatsoever. Neither party shall have any right or authority to assume
         or create any obligation or responsibility for or on behalf of the
         other party or to otherwise bind the other party.

                                       20
<PAGE>

18.5     The parties recognize that this is a master Agreement covering a number
         of countries. If for any country in the Territory it becomes necessary
         to execute a separate instrument for such country in order to satisfy
         local regulatory requirements, the parties agree to execute such
         further instrument; that shall to the extent permitted by the laws of
         the country conform to the terms and conditions of this Agreement.

18.6     This Agreement and the Schedules and Exhibits hereto are originally
         prepared and signed in the English language. If any translation into
         any other language is legally required for purposes of governmental
         filings, the parties shall arrange for such translation, and the costs
         thereof shall be borne by the party legally required to make such
         filing. In the event of any question or dispute as to the meaning or
         interpretation of any term, condition or provision of this Agreement,
         or any Schedule or Exhibit hereto, the English language version shall
         in all events govern for all purposes whatsoever.

18.7     Termination of this Agreement for any reason, or expiration of this
         Agreement, will not affect: (i) obligations, including the payment of
         any Scheduled Payments or royalties that have accrued as of the date of
         termination or expiration, and (ii) rights and obligations which, from
         the context thereof, are intended to survive termination or expiration
         of this Agreement.

18.8     This Agreement is executed simultaneously in counterparts, each of
         which shall be deemed an original, but all of which shall constitute
         but one and the same instrument.

WYETH HOLDINGS CORPORATION             DOV PHARMACEUTICAL, INC.

NAME: /s/ Robert A. Dougan             NAME: /s/ Robert Horton
TITLE: Senior Vice President           TITLE: Vice President and General Counsel
DATE:       2/25/04                    DATE:  ________________________

                                       21
<PAGE>

                                   SCHEDULE 1

                                    PRODUCTS

                                   CL 285,489

                                       22
<PAGE>

                                    EXHIBIT A

                                  WYETH PATENTS

CL 285,489

United States

U.S. 6,399,621  expires 8/9/2020
U.S. 4,900,836  expires 2/13/2007
U.S. 4,521,422  expires 6/23/2003

                                       23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]